Researchers at Guangzhou Laboratory and Guangzhou Medical University have described compounds reported to be useful for the treatment of asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and infectious pneumonia.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) potentially useful for the treatment of cancer. The ADCs comprise an antibody or antigen-binding fragment linked to a cytotoxic drug through a linker.

Abbisko Therapeutics Co. Ltd. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR (HER1; erbB1)-targeting moiety through a linker.

Genescience Pharmaceuticals Co. Ltd. has disclosed tachykinin NK3 receptor (TACR3) antagonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), cancer, convulsions, depression and more.

Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors reported to be useful for the treatment of cancer, infections, autoimmune diseases, cardiovascular diseases, inflammatory disorders and neurological conditions.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged dihydrofuro[3,4-f]quinazoline compounds acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Genescience Pharmaceuticals Co. Ltd. has identified sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria (PKU).

Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) E542K mutant inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).

China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has disclosed heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.